These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 22784966

  • 1. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T, Finazzi MC, Finazzi G.
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [Abstract] [Full Text] [Related]

  • 2. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 3. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 4. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 5. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A, Barbui T.
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [Abstract] [Full Text] [Related]

  • 6. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [Abstract] [Full Text] [Related]

  • 8. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 9. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 10. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 11. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Dec; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 12. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 13. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G, Barbui T.
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [Abstract] [Full Text] [Related]

  • 14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 15. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [Abstract] [Full Text] [Related]

  • 16. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [Abstract] [Full Text] [Related]

  • 17. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 18. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [Abstract] [Full Text] [Related]

  • 19. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
    Finazzi G, low-dose aspirin in polycythemia (ECLAP).
    Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
    [Abstract] [Full Text] [Related]

  • 20. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
    Landolfi R, Marchioli R.
    Semin Thromb Hemost; 1997 Jun; 23(5):473-8. PubMed ID: 9387206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.